Glen Santangelo
#1305 out of 1697 analysts
Barclays
Automatically Tracked
Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
Gain and growth charts are calculated per selected timeframe:
-10.05%
Gain +0.04%
Monthly
-0.5%
Yearly
-5.85%
Drawdown
52.6%
$80,323.96
Equity
Holdings
$23,732.33
Cash
$56,591.63
Investment
$23,885.71
-$52,370.68
Profit +$30.86
Realized
-$52,217.31
Unrealized
-$153.38
Dividends
$1,559.63
$56,591.63
Cash
Deposits
$132,694.64
Withdrawals
$0
Commissions
$0
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
0.04%
Profit
$30.86
Win %
33%
This Week
Compared To Last Week
Gain
0.04%
Profit
$30.86
Win %
33%
This Month
Compared to last month
Gain
-4.23%
Profit
-$3,544.21
Win %
54%
This Year
Compared to last year
Gain
-3.86%
Profit
-$3,226.33
Win %
50%
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 498 | Longs Won 148/423 34% | Profit Factor 0.49 |
| Profitability | Shorts Won 12/75 16% | Standard Deviation $1,189.32 |
| Average Win $322.43 | Best Trade (Aug 02) $6,745.23 | Sharpe Ratio -428.53 |
| Average Loss -$312.19 | Worst Trade (Jun 25) -$14,566.27 | Z-Score -2.23 (100%) |
| Commissions $0 | Avg. Trade Length 1m 1w 3d | Expectancy -$105.16 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 257 | 232 | 206 | 180 | 154 | 129 | 103 | 77 | 51 | 26 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
 COLL Collegium Pharmaceutical Inc. | 140.25 | $4,030.82 | $3,835.87 | - | -$194.95 | -4.84% | +0.885% |
 GDRX GoodRx Holdings, Inc. Class A Common Stock | -4,664.19 | $16,091.45 | $16,091.45 | - | - | - | 0.0 |
 XERS Xeris Biopharma Holdings, Inc. | 437.61 | $3,763.44 | $3,805.02 | - | $41.58 | 1.1% | -0.057% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
